Crossmark

Safety of a cytomegalovirus-specific hyperimmunoglobulin in the prevention of maternal–fetal transmission after primary infection—results of an open-label, single-arm, prospective trial

Crossref DOI link: https://doi.org/10.1007/s00404-026-08311-8

Published Online: 2026-01-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kagan, Karl Oliver https://orcid.org/0000-0003-1497-5143
Enders, Martin https://orcid.org/0000-0003-3218-074X
Schneider, Michael Oliver

Geipel, Annegret https://orcid.org/0000-0001-8602-8925
Jückstock, Julia

Siedentopf, Jan-Peter https://orcid.org/0000-0002-8820-0116
Faschingbauer, Florian

Gechev, Dimitar Emilov

Jaskolski, Michael Robert https://orcid.org/0000-0002-2375-3916
Rohr, Irena https://orcid.org/0000-0002-9810-9092
Schütze, Joachim

Aigner, Silke

Lentze, Stephan

Staiger, Christiane https://orcid.org/0000-0001-8687-7687
Funding

Funding for this research was provided by:

Biotest
License Information

Text and Data Mining valid from 2026-01-09

Version of Record valid from 2026-01-09
More Information

Article History

Received: 18 November 2025

Accepted: 5 January 2026

First Online: 9 January 2026

Declarations

:

: KOK is editor-in-chief of this journal and was coordinating investigator of the reported trial. ME was responsible for the laboratory analyses. MOS, AG, JJ, and JPS were principal investigators of further active sites. FF, IR, DG, were investigators, MRJ was co-investigator. JS, SA, SL and CS are employees of Biotest AG.

: The appropriate trial-related documents were reviewed and approved by the competent local Independent Ethics Committees.

Document is current

Any future updates will be listed below